|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005527,
umls-concept:C0007634,
umls-concept:C0035647,
umls-concept:C0045093,
umls-concept:C0078257,
umls-concept:C0205179,
umls-concept:C0205195,
umls-concept:C0205216,
umls-concept:C0205314,
umls-concept:C0600688,
umls-concept:C0679622,
umls-concept:C0684249,
umls-concept:C1704419
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-7-18
|
|
pubmed:abstractText |
Gemcitabine and vinorelbine are two of the most active third-generation agents for the treatment of advanced nonsmall cell lung carcinoma (NSCLC). The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:BlumenscheinGeorgeGJr,
pubmed-author:BooksC ACA,
pubmed-author:FossellaFrank VFV,
pubmed-author:GlissonBonnie SBS,
pubmed-author:HerbstRoy SRS,
pubmed-author:HongWaun KiWK,
pubmed-author:JungMaria SMS,
pubmed-author:KhuriFadlo RFR,
pubmed-author:KiesMerrill SMS,
pubmed-author:KurieJonathan MJM,
pubmed-author:LeeJ JackJJ,
pubmed-author:LiuDiane DDD,
pubmed-author:LuCharlesC,
pubmed-author:LuRobertR,
pubmed-author:MundenReginald FRF,
pubmed-author:PapadimitrakopoulouVassiliki AVA,
pubmed-author:PistersKatherine M WKM,
pubmed-author:ShinDong MDM,
pubmed-author:ZinnerRalphR
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
340-53
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12124835-Adult,
pubmed-meshheading:12124835-Aged,
pubmed-meshheading:12124835-Antimetabolites, Antineoplastic,
pubmed-meshheading:12124835-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:12124835-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12124835-Biological Therapy,
pubmed-meshheading:12124835-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:12124835-Combined Modality Therapy,
pubmed-meshheading:12124835-Deoxycytidine,
pubmed-meshheading:12124835-Disease Progression,
pubmed-meshheading:12124835-Female,
pubmed-meshheading:12124835-Humans,
pubmed-meshheading:12124835-Lung Neoplasms,
pubmed-meshheading:12124835-Male,
pubmed-meshheading:12124835-Middle Aged,
pubmed-meshheading:12124835-Survival Rate,
pubmed-meshheading:12124835-Vinblastine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
|
|
pubmed:affiliation |
Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. rherbst@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
